By Sabela OjeaShares of Poseida Therapeutics on Monday climbed after the company said it received positive early results from the phase 1 trial for a blood cancer treatment. The stock has, however, dropped 75% in the past 12 months. The clinical-stage cell and gene therapy company said its early P-BCMA-ALLO1 clinical results inspire it to further develop the treatment for relapsed-refractory multiple myeloma in partnership with Roche. Last year, Poseida said it signed a strategic collaboration with the biotechnology company Roche. Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix(END) Dow Jones Newswires12-11-23 1016ET

Source: Wall Street Journal December 11, 2023 16:55 UTC